A Study of PLX51107 in Advanced Malignancies

Phase 1

Terminated

• Conditions: Myelodysplastic Syndrome; Solid Tumors; Acute Myeloid Leukemia; Non-Hodgkin's Lymphoma
• Interventions: Drug: PLX51107

• Registration Number: NCT02683395
• Lead Sponsor: Plexxikon

Brief Summary

The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the investigational drug PLX51107 in subjects with advanced solid tumors (including lymphoma), and advanced hematological malignancies

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-02-12
• Study First Submitted QC: 2016-02-12
• Study First Posted: 2016-02-17
• Study Start: 2016-03
• Primary Completion: 2018-09
• Study Completion: 2018-09
• Status Verified: 2018-12
• Last Update Submitted: 2018-12-20
• Last Update Posted: 2018-12-24

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1. Confirmed diagnosis of a relapsed or refractory malignancy in 1 of 2 treatment groups:

   1. Group A: Subjects with any solid tumor (including lymphomas).
   2. Group B: Subjects with relapsed or refractory AML, Subjects with relapsed or refractory high-risk MDS, defined as revised International Prognostic Scoring System (IPSS-R) intermediate or greater disease.

2. Age ≥18 years.

3. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

4. Life expectancy ≥3 months in the judgment of the investigator.

5. Adequate organ function.

6. Group A subjects must have measurable or evaluable disease per the appropriate disease criteria.

7. Women of child-bearing potential must have a negative serum pregnancy test at Screening and must agree to use an effective form of contraception from the time of the negative pregnancy test up to 6 months after the last dose of study drug. Effective forms of contraception include abstinence, hormonal contraceptive in conjunction with a barrier method, or a double barrier method. Women of non-child-bearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥1 year.

8. Fertile men must agree to use an effective method of birth control during the study and for up to 6 months after the last dose of study drug.

9. All associated clinically significant toxicity from previous cancer therapy must be resolved (to ≤Grade 1 or baseline) prior to study treatment administration (Grade 2 alopecia is allowed).

10. Willingness and ability to provide written informed consent prior to any study-related procedures and to comply with all study requirements.

Exclusion Criteria

1. Prior exposure to a bromodomain inhibitor, such as OTX-015 or CPI-0610.
2. Allogenic or autologous transplant for hematological malignancy with infusion of stem cells within 90 days before Cycle 1 Day 1, or on active immunosuppressive therapy for graft-versus-host disease (GVHD) or GVHD prophylaxis within 2 weeks of Cycle 1 Day 1.
3. Known uncontrolled fungal, bacterial, and/or viral infection ≥Grade 2.
4. Uncontrolled autoimmune hemolytic anemia or thrombocytopenia.
5. For Group A: Subjects with a history of brain metastases are ineligible. This includes previously treated brain metastases. For Group B (subjects with AML): Active symptomatic CNS involvement of AML. Subjects with previously treated leptomeningeal disease that has been effectively treated are eligible.
6. A diagnosis of acute promyelocytic leukemia (APL) or chronic myeloid leukemia (CML) in blast crisis.
7. Known or suspected allergy to the investigational agent or any agent given in association with this trial.
8. Women who are pregnant or are breast feeding.
9. Clinically significant cardiac disease
10. Inability to take oral medication or significant nausea and vomiting, malabsorption, or significant small bowel resection that, in the opinion of the Investigator, would preclude adequate absorption.
11. Subject with known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection or is known to be a carrier of hepatitis B or C.
12. Strong CYP3A4 and CYP2C8 inhibitors or inducers or CYP3A4 substrate drugs with a narrow therapeutic range taken within 14 days or 5 drug half-lives before start of study drug.
13. Active secondary malignancy
14. Major surgery or significant traumatic injury within 14 days prior to therapy
15. Receipt of anti-cancer therapy 14 days prior to Cycle 1 Day 1
16. Presence of any other medical, psychological, familial, sociological, or geographic condition potentially hampering compliance with the study protocol Subjects who are participating in any other therapeutic clinical study (observational or registry trials are allowed).
17. Subjects who have Burkitt's lymphoma or Burkitt-like lymphoma.
18. Subjects on active anticoagulation therapy including warfarin, factor Xa inhibitors, thrombin inhibitors, or heparin.
19. Subjects with documented hepatic metastases involving >50% of the hepatic parenchyma.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Treatment Group B	PLX51107	Open label, sequential PLX51107 dose escalation in approximately 30 subjects with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
Treatment Group A	PLX51107	Open label, sequential PLX51107 dose escalation in approximately 30 solid tumor subjects.

Primary Outcome Measures

Name	Time	Method
Area under the concentration-time curve (AUC) of PLX51107.	1 year
Half life (t1/2) of PLX51107.	1 year
Time to peak concentration (Tmax) of PLX51107.	1 year
Safety of PLX51107 as measured by adverse events and serious adverse events.	1 year
Maximum observed concentration (Cmax) of PLX51107.	1 year

Secondary Outcome Measures

Name	Time	Method
Progression-Free Survival (PFS).	1 year	PFS time is defined as the time from the first dose of PLX51107 to disease progression or death, whichever occurs first.
Overall Survival (OS).	1 year	OS is defined as the first dose of study drug until the date of death from any cause.
Overall Response Rate (ORR)	1 year	ORR is defined as the total number of patients with the best overall response according to standard criteria for the relevant malignancy divided by the total number of treated patients and expressed as a percentage.
Duration Of Response (DOR).	1 year	DOR is defined as the time from the initial objective response to disease progression or death, whichever occurs first.

Trial Locations

Locations (5)

The Ohio State University Stephanie Spielman Comprehensive Breast Center; 🇺🇸 Columbus, Ohio, United States

Columbia University Medical Center; 🇺🇸 New York, New York, United States

South Texas Accelerated Research Therapeutics; 🇺🇸 San Antonio, Texas, United States

MUSC/ Hollings Cancer Center; 🇺🇸 Charleston, South Carolina, United States

Thomas Jefferson University; 🇺🇸 Philadelphia, Pennsylvania, United States